Compare Natera Inc. Common Stock (NTRA) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Petróleo Brasileiro SA — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Petróleo Brasileiro SA trades at $25.95 (market cap $157.24B). The key difference: Petróleo Brasileiro SA is far larger — about 2.8× Natera Inc. Common Stock's market cap, and Petróleo Brasileiro SA pays a 6.57% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Petróleo Brasileiro SA for 26 Days on average.
| NTRA | PBR | |
|---|---|---|
Market Cap | $57.03B | $157.24B |
Volume | 1,131,157 | 17,564,454 |
Sector | Health | Energy |
52-Week High | $425.64 | $25.94 |
52-Week Low | $179.42 | $11.54 |
Typical Hold Time | 0 Days | 26 Days |
Enterprise Value | $56.18B | $217.66B |
Dividend Yield | — | 6.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Petrobras (PBR) trades at $25.50, up 0.31% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings that beat estimates, with net income nearly doubling year-over-year on record production. Recent news highlights a new oil discovery off Amapa and a 22-year LNG supply deal with Cheniere Energy, supporting long-term growth prospects.
PBR presents a compelling value with a low P/E of 6.44 and robust profitability, including a 30.77% ROE. However, the stock trades above the analyst consensus price target of $22.33, and net cash flow turned negative in 2026. Key risks include political interference in Brazil, volatile oil prices, and execution challenges in new projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
